Skip to content
Review

A Novel Patient-Centered Severity Measure for Pilonidal Disease: A Retrospective Cohort Study.

Oct 2026 · Journal of Surgical Research · Vol 327, pp. 509-517 · 0 citations · 37 references
Medicine

Abstract

INTRODUCTION Pilonidal disease is common in adolescents and young adults and can impair daily functioning during an important developmental phase. This study aimed to develop and validate a pilonidal disease severity score based on patient-reported symptom burden and social quality of life, and compare it with the International Pilonidal Society classification, an anatomy-based system categorizing pilonidal disease by location and distribution.

Methods

Retrospective review of patients with pilonidal disease presenting to a Pilonidal Care Clinic (January 2023-August 2025). Of 620 new patients, 447 met inclusion criteria and were analyzed, with 299 in the derivation cohort and 148 in the validation cohort. Symptom burden score (0-18) was calculated. Quality of life was measured across six domains (each 0-10) and reduced to a three-domain score (0-30). Multivariable linear regressions adjusted for age and gender were used.

Results

Nidus and rash were associated with 2.57 and 2.45-point increases, respectively, in the 18-point symptom burden score (P < 0.001, 95% confidence interval: 1.53-3.60; P < 0.001, 95% confidence interval: 1.10-3.80). One point was assigned for three or more pits, 0 for wound, and 10 each for nidus and rash, yielding mild (0-1), moderate (10-11), and severe (20-21) categories. Symptom burden increased across categories in both cohorts (P < 0.001). Severity category was also associated with worse social quality of life (P < 0.001, P = 0.006); International Pilonidal Society classification was not correlated with either.

Conclusions

A patient-centered pilonidal disease severity score may improve severity classification and comparability of outcomes across studies.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.